News & Updates

A novel microbiome technology developed by researchers at the Chinese University of Hong Kong (CUHK) enhances faecal microbiota transplantation (FMT) success rate to >90 percent in patients with recurrent Clostridioides difficile infection (CDI). FMT with the novel technology will become available in public hospitals in Hong Kong.

The oral, dual peroxisome proliferator-activated receptor-α/δ agonist elafibranor improves biomarkers of cholestasis and quells itching in patients with primary biliary cholangitis, while having an acceptable safety profile, as shown in the phase III ELATIVE study.

Continuous feeding appears to be more effective than intermittent feeding in reducing the rate of mortality in critically ill patients in the intensive care unit (ICU), reveals a study.

Long-term monthly treatment with givosiran has good tolerability and offers continuous improvements to patients with acute hepatic porphyria (AHP), results of the phase III ENVISION trial have shown.

For patients with ulcerative colitis who are receiving vedolizumab, dose optimization may not be required in the presence of early nonresponse to treatment as well as high drug clearance, according to data from the phase IV ENTERPRET study.

A systematic review and meta-analysis by researchers from the University of Hong Kong has shown that the use of peripherally inserted central catheters (PICCs) is associated with a higher rate of complications than central lines in terminally ill cancer patients with central venous access devices (CVADs) for palliative care. No conclusions were reached regarding the use of totally implanted ports (PORTs), as no studies on PORTs were eligible for analysis.